A new clinical trial called REVIVE is being launched to test whether the antibiotic azithromycin can help reduce deaths in adults with advanced HIV disease. The trial will be conducted in 19 African countries and will involve 8,000 participants.
The REVIVE trial is being led by researchers at the University of Cape Town (UCT) and the Population Health Research Institute (PHRI) in Canada. The trial is funded by the Bill & Melinda Gates Foundation.
The researchers believe that azithromycin may help to reduce deaths in people with advanced HIV disease by preventing bacterial infections. These infections are a common cause of death in people with HIV.
The REVIVE trial is a double-blinded, placebo-controlled trial. This means that neither the participants nor the researchers will know who is receiving azithromycin and who is receiving a placebo.
The trial is expected to last for two years. The results of the trial will be used to determine whether azithromycin should be added to the standard of care for people with advanced HIV disease in Africa.
Source
https://www.phri.ca/research/revive/
https://www.phri.ca/
